A Phase 2 interventional study of high-definition transcranial direct current stimulation and modified constraint-induced language therapy in Primary Progressive Aphasia, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by University of Pennsylvania · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Aphasia, Primary Progressive with a site in United States — 20 open to participants now, 24 under way, none of them phase 3. Aphasia, Primary Progressive · United States.
Among the 51 studies in Aphasia, Primary Progressive with a site in United States, this one is the 12th largest by enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2020, is one of 5 in phase 2, and was the 19th registered.
77 studies on the registry are indexed under Aphasia, Primary Progressive; 28 are open to participants now.
Browse Aphasia, Primary Progressive studies →20 of the 51 studies in Aphasia, Primary Progressive with a site in United States are open now. Recruiting first, the newest first:
Medical College of Wisconsin · Sites in United States
Ages 45+
Maya Henry · Sites in United States
Ages 40+
Maya Henry · Sites in United States
Ages 40+
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
Oregon Health and Science University · Sites in United States
Ages 18–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Aphasia, Primary Progressive studies recruiting now, 13 (54%) set no upper age limit and 1 (4%) stops at 75 or younger; 1 takes children under 18; 10 take healthy volunteers.
This study: 45 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 4 1
First in 2007; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 30 across 60 interventional studies indexed under Aphasia, Primary Progressive.
Median enrollment 30 across the 43 interventional studies, 170 across the 8 observational. Of the 26 that completed or were terminated, 14 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 51 have an industry lead sponsor. The 10 most frequent:
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
University of Pennsylvania has 5 studies filed under Aphasia, Primary Progressive — fewer than ten, so there is no comparison to draw.
10 of the studies in Aphasia, Primary Progressive with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06066710University of Missouri-ColumbiaPropranolol in Primary Progressive Aphasia | 2026-12 |
| NCT04920318University of ArizonaEnhancing Language Function in Primary Progressive Aphasia | 2026-12-30 |
| NCT00537004Northwestern UniversityLanguage in Primary Progressive Aphasia | 2027-04 |
| NCT06064890AviadoBio LtdA Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) | 2027-04-01 |
| NCT05368350The University of Texas at DallasTreating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation | 2027-04-16 |
Add all 10 to your calendar (.ics) → With an account.
Among the 51 studies in Aphasia, Primary Progressive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a double-blind, sham-controlled, crossover study in which subjects with the non-fluent/agrammatic and logopenic variants of primary progressive aphasia (naPPA and lvPPA, respectively) will undergo language testing and structural and functional brain imaging before and after receiving 10 semi-consecutive daily sessions of real or sham high-definition transcranial direct current stimulation (HD-tDCS) paired with modified constraint-induced language therapy (mCILT). Language testing and brain imaging will be repeated immediately after completion of and 3 months following completion of treatment. The 3-month follow-up will be the primary endpoint. The investigators will examine changes in language performance induced by HD-tDCS + mCILT compared to sham HD-tDCS + mCILT. The investigators will also use network science to analyze brain imaging (fMRI) data to identify network properties associated with baseline PPA severity and tDCS-induced changes in performance. This study will combine knowledge gained from our behavioral, imaging, and network data in order to determine the relative degrees to which these properties predict whether persons with PPA will respond to intervention.
The central framework for the project is a double-blind, sham-controlled, crossover study in which subjects with the non-fluent/agrammatic and logopenic variants of primary progressive aphasia (naPPA and lvPPA, respectively) will undergo language testing and structural and functional brain imaging before and after receiving 10 semi-consecutive daily sessions of real or sham high definition transcranial direct current stimulation (HD-tDCS) paired with modified constraint-induced language therapy (mCILT). Language testing and brain imaging will be repeated immediately after completion of and 3 months following completion of treatment.
Subjects with naPPA and lvPPA will be randomized to one of two study arms: HD-tDCS+mCILT or sham stimulation+mCILT paired with pre- and post-stimulation imaging and behavioral measures. Equal numbers of subjects with naPPA and lvPPA will be randomized to the HD-tDCS + mCILT and sham + mCILT study arms. The study is double-blinded, in that neither the subject nor the study personnel administering HD-tDCS or sham stimulation will know which arm of the study the subject has been randomized into. Study coordinators will administer HD-tDCS by entering a pre-determined code that has been programmed into the device by another member of the study team. Data will be digitally audio-recorded and analyzed off-line, such that study team members performing data coding and analysis will likewise be blinded to the treatment condition of each subject.
Subject participation in this protocol will occur during 27 planned visits that will span approximately 8 months. The events of the study visits are described below:
VISIT 1:
a Informed consent and screening b. Baseline language assessment #1 c. Baseline MRI scanning
VISIT 2:
Baseline language assessment #2
VISITS 3-11:
HD-tDCS+mCILT OR sham stimulation+mCILT, depending on the study arm to which they had been randomized.
VISIT 12:
VISIT 13:
6-Week follow-up language assessment
VISIT 14:
**CROSSOVER**
VISIT 15:
Crossover baseline language assessment #2
VISITS 16-24:
HD-tDCS+mCILT or sham stimulation+mCILT
VISIT 25:
VISIT 26:
6 Week follow-up language assessment:
VISIT 27:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of HD-tDCS for 20 minutes using a montage in which a central electrode (1.5mA) is placed over the left frontotemporal area and four surrounding cathodes (.375mA each). Subjects will participate in a modified constraint-induced language therapy.
Device: high-definition transcranial direct current stimulation · Behavioral: modified constraint-induced language therapy
Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of sham for 20 minutes using a montage in which a central electrode is placed over the left frontotemporal area and four surrounding cathodes. Subjects will participate in a modified constraint-induced language therapy,
Device: high-definition transcranial direct current stimulation · Behavioral: modified constraint-induced language therapy
High definition transcranial direct current stimulation (HD-tDCS) involves the application of low-intensity current through electrodes placed on the scalp. It is believed to elicit brain effects by producing incremental shifts in the resting membrane potential of large numbers of neurons, which alters neuronal firing rates and thus modulates patterns of brain activity in potentially behaviorally-relevant ways. HD-tDCS differs from conventional transcranial direct current stimulation (tDCS) because it employed smaller electrodes configured in such a way as to deliver more focal stimulation of the brain.
Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
Change in Western Aphasia Battery Aphasia Quotient (WAB-AQ)
The primary outcome measure will be the change in score on the WAB-AQ, a score assessing overall aphasia recovery. Scores can range from 0-100. 0-25 is very severe, 26-50 is severe, 51-75 is moderate, and 76-above is mild. A score of 93 or higher is considered recovered.
Time frame: At baseline, immediately after 2 week intervention, 6 and 12 weeks post intervention for HD-tDCS+mCILT and Sham intervention periods.
Participants were recruited from March 2020 - October 2024 from the Hospital of the University of Pennsylvania and surrounding Philadelphia area medical centers.
| Milestone | HD-tDCS+mCILT First, Then Sham + mCILT | Sham+mCILT First, Then HD-tDCS + mCILT |
|---|---|---|
| Started | 30 | 32 |
| Completed | 30 | 31 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
The primary outcome measure will be the change in score on the WAB-AQ, a score assessing overall aphasia recovery. Scores can range from 0-100. 0-25 is very severe, 26-50 is severe, 51-75 is moderate, and 76-above is mild. A score of 93 or higher is considered recovered.
| Scores on a scale | HD-tDCS+mCILT First, Then Sham + mCILT | Sham+mCILT First, Then HD-tDCS + mCILT |
|---|---|---|
| Baseline Hd-tdcs + Mcilt | 81.3 ± 12.46 | 81.26 ± 11.99 |
| 0 weeks post-Hd-tdcs + Mcilt | 82.52 ± 11.52 | 81.68 ± 11.56 |
| 6 weeks post-Hd-tdcs + Mcilt | 81.96 ± 11.91 | 81.40 ± 11.68 |
| 12 weeks post-Hd-tdcs + Mcilt | 81.45 ± 12.40 | 80.17 ± 12.92 |
| Baseline Sham+mcilt | 81.45 ± 12.40 | 79.99 ± 13.07 |
| 0 weeks post-Sham+mcilt | 81.88 ± 12.89 | 82.04 ± 11.48 |
| 6 weeks post-Sham+mcilt | 82.60 ± 12.48 | 82.16 ± 11.45 |
| 12 weeks post-Sham+mcilt | 80.55 ± 15.17 | 80.43 ± 13.32 |
Collected over From baseline, adverse event data were collected over a period of time consisting of 36 weeks (12 weeks for arm 1 and 24 weeks for arm 2).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HD-tDCS + mCILT | 0/62 (0%) | 1/62 (1.6%) | 12/62 (19.4%) |
| Sham + mCILT | 0/62 (0%) | 3/62 (4.8%) | 10/62 (16.1%) |
| Event | HD-tDCS + mCILT | Sham + mCILT |
|---|---|---|
| Cancer DiagnosisGeneral disorders | 0/62 | 1/62 |
| Fall resulting in broken bone/fractureGeneral disorders | 1/62 | 1/62 |
| Hernia + repairSurgical and medical procedures | 0/62 | 1/62 |
| Event | HD-tDCS + mCILT | Sham + mCILT |
|---|---|---|
| HeadacheGeneral disorders | 5/62 | 2/62 |
| FallGeneral disorders | 3/62 | 0/62 |
| Skin IrritationSkin and subcutaneous tissue disorders | 0/62 | 3/62 |
| Jaw PainGeneral disorders | 1/62 | 0/62 |
| Herniated discMusculoskeletal and connective tissue disorders | 1/62 | 0/62 |
| MigraineNervous system disorders | 1/62 | 0/62 |
| ShinglesInfections and infestations | 1/62 | 0/62 |
| Viral InfectionInfections and infestations | 1/62 | 0/62 |
| Skin biopsySkin and subcutaneous tissue disorders | 1/62 | 0/62 |
| Head discomfortGeneral disorders | 0/62 | 1/62 |
| Age, Continuous(years) | HD-tDCS + mCILT First, Then Sham + mCILT | Sham+mCILT First, Then HD-tDCS + mCILT | Total |
|---|---|---|---|
| Mean | 68.8 ± 8.25 | 67.9 ± 7.61 | 68.2 ± 7.95 |
| Sex: Female, Male(Participants) | HD-tDCS + mCILT First, Then Sham + mCILT | Sham+mCILT First, Then HD-tDCS + mCILT | Total |
|---|---|---|---|
| Female | 14 | 15 | 29 |
| Male | 16 | 17 | 33 |
| Ethnicity (NIH/OMB)(Participants) | HD-tDCS + mCILT First, Then Sham + mCILT | Sham+mCILT First, Then HD-tDCS + mCILT | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 30 | 31 | 61 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | HD-tDCS + mCILT First, Then Sham + mCILT | Sham+mCILT First, Then HD-tDCS + mCILT | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 29 | 32 | 61 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Western Aphasia Battery (WAB-AQ) Score(scores on a scale) | HD-tDCS + mCILT First, Then Sham + mCILT | Sham+mCILT First, Then HD-tDCS + mCILT | Total |
|---|---|---|---|
| Mean | 81.52 ± 12.18 | 80.08 ± 12.66 | 80.77 ± 12.45 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2020 to primary completion in Jun 2025, 58 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aphasia, Primary Progressive →